Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06953999 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Phase III Study of Ivonescimab + Chemo With/Without AK117 in Metastatic Pancreatic Cancer

StatusRecruiting
PhasePhase 3
SponsorAkeso
Started2025-06-11
View on ClinicalTrials.gov ↗

Amendment history

2026-03-02
Not Yet Recruiting→Recruiting Study Identification, Study Status, Contacts/Locations v1
Trial statusNot Yet Recruiting→Recruiting
Start dateestimated 2025-05-14→confirmed 2025-06-11
Study sites2→3
Study title-9 characters
A Phase III Study of Ivonescimab + Chemo With/Without AK117 vs Chemo in Metastatic Pancreatic Cancer
2025-04-24
Original filing
Akeso
96 trials monitored
See 1 trial at risk
Pancreatic Cancer
1,634 trials monitored
See 90 trials at risk
This is a Phase 3, randomized, double-blind clinical trial aimed at evaluating the efficacy and safety of Ivonescimab plus chemotherapy with or without AK117 versus placebo plus chemotherapy in patients with metastatic pancreatic cancer. The study seeks to determine whether the addition of Ivonescimab and/or AK117 improves clinical outcomes compared to standard chemotherapy alone. Participants will be randomly assigned to receive either Ivonescimab with/without AK117 or placebo, both in combination with chemotherapy.
Trial Details
NCT Number NCT06953999
Lead Sponsor Akeso
Conditions Pancreatic Cancer
Enrollment 999 participants
Start Date 2025-06-11
Primary Completion 2027-05-14 (estimated)
Study Completion 2028-05-14 (estimated)
Updated on ClinicalTrials.gov 2026-03-04